title: The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study.
abstract: BACKGROUND
  The Menopause Rating Scale is a health-related Quality of Life scale developed in the early 1990s and step-by-step validated since then. No methodologically detailed work on the utility of the scale to assess health-related changes after treatment was published before.
  
  
  METHODS
  We analysed an open, uncontrolled post-marketing study with over 9000 women with pre- and post-treatment data of the MRS scale to critically evaluate the capacity of the scale to measure the health-related effects of hormone treatment independent from the severity of complaints at baseline.
  
  
  RESULTS
  The improvement of complaints during treatment relative to the baseline score was 36% in average. Patients with little/no complaints before therapy improved by 11%, those with mild complaints at entry by 32%, with moderate by 44%, and with severe symptoms by 55% - compared with the baseline score. We showed that the distribution of complaints in women before therapy returned to norm values after 6 months of hormone treatment. We also provided weak evidence that the MRS results may well predict the assessment of the treating physician. Limitations of the study, however, may have lead to overestimating the utility of the MRS scale as outcome measure.
  
  
  CONCLUSIONS
  The MRS scale showed some evidence for its ability to measure treatment effects on quality of life across the full range of severity of complaints in aging women. This however needs confirmation in other and better-designed clinical/outcome studies.
authors.affiliation: Center for Epidemiology & Health Research Berlin, Invalidenstr, 115, 10115 Berlin, German. Heinemann@zeg-berlin.de
authors.forename: Lothar A J
authors.initials: LA
authors.lastname: Heinemann
authors.forename: Thai
authors.initials: T
authors.lastname: DoMinh
authors.forename: Frank
authors.initials: F
authors.lastname: Strelow
authors.forename: Silvia
authors.initials: S
authors.lastname: Gerbsch
authors.forename: Jörg
authors.initials: J
authors.lastname: Schnitker
authors.forename: Hermann P G
authors.initials: HP
authors.lastname: Schneider
mesh_terms: D000328:Adult; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D004338:Drug Combinations; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D052776:Female Urogenital Diseases / Q000150:complications / Q000523:psychology; D005858:Germany; D006176:Gynecology; D020249:Hormone Replacement Therapy / Q000523:psychology*; D006801:Humans; D008593:Menopause / Q000187:drug effects* / Q000523:psychology; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000379:methods*; D017060:Patient Satisfaction; D011358:Product Surveillance, Postmarketing; D011594:Psychometrics / Q000295:instrumentation*; D011788:Quality of Life / Q000523:psychology*; D011795:Surveys and Questionnaires; D016387:Women's Health
chemical_list: D004338:Drug Combinations; C103294:estradiol valerate, cyproterone acetate drug combination; D017373:Cyproterone Acetate; D004958:Estradiol